470 A phase 1/2, open-label, dose escalation and expansion study of GI-101 as a single agent and in combination with a pembrolizumab, lenvatinib or local RT in advanced solid tumors (KEYNOTE-B59)
oleh: Byoung Chul Cho, Jae-Lyun Lee, Myoung Ho Jang, Hyung Soon Park, Byoung Yong Shim, Sang Joon Shin, Nari Yun, Mina Ham, Young Jun Koh
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2021-11-01 |
Deskripsi
No description available for this item.